TMCnet News
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022GAITHERSBURG, Md., June 17, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver CongressTM 2022, to be held in London, UK on June 22-26, 2022. Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Details for the oral presentation are as follows:
Preceding Dr. Harrison’s presentation of the Phase 1 data, Dr. Scott Harris, Chief Medical Officer of Altimmune, will participate in the 2nd Official ILC 2022 Press Conference in which he will provide a brief overview of the study findings and answer questions. Details of the press conference are as follows:
About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Investor & Media Contacts: Richard Eisenstadt
|